Search

Your search keyword '"J. I. Weitz"' showing total 81 results

Search Constraints

Start Over You searched for: Author "J. I. Weitz" Remove constraint Author: "J. I. Weitz"
81 results on '"J. I. Weitz"'

Search Results

1. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study

2. OP0269 BIOMARKERS TO PREDICT RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS

3. Corrigendum to 'Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study' [Thromb. Res. vol. 185, January 2020, pages 13-19]

4. Addressing the burden of hospital‐related venous thromboembolism: the role of extended anticoagulant prophylaxis

5. Once versus twice daily aspirin after coronary bypass surgery: a randomized trial

7. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

8. Rapid quantitative D‐dimer to exclude pulmonary embolism: a prospective cohort management study

9. Medical device‐induced thrombosis: what causes it and how can we prevent it?

10. Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial

11. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

12. D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment

14. Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model

15. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial

16. Real-world variability in dabigatran levels in patients with atrial fibrillation

17. New anticoagulants

18. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor

19. A Protease TAMER: a nucleic acid‐based anticoagulant

22. Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial

23. Guidance, guidelines, and communications

24. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents

25. Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells

27. A novel antithrombin-heparin covalent complex

28. A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process

29. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

30. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

31. New Antithrombotics

32. Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation

33. Elevated tissue factor procoagulant activity in CD133-positive cancer cells

35. Free Protein S Deficiency May Be Found in Patients with Antiphospholipid Antibodies who Do not Have Systemic Lupus Erythematosus

36. Heparin compromises streptokinase-induced arterial patency in rabbits

38. APIXABAN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: DATA FROM THE AMPLIFY TRIAL

39. New anticoagulant drugs

40. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study

41. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin

44. The mechanism of action of thrombin inhibitors

45. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group

46. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator

47. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes

48. Thrombosis and anticoagulation

49. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells

50. A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats

Catalog

Books, media, physical & digital resources